StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report released on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
NASDAQ EVOK opened at $0.58 on Friday. Evoke Pharma has a 1 year low of $0.40 and a 1 year high of $1.77. The company has a market capitalization of $4.95 million, a PE ratio of -0.31 and a beta of 0.38. The company has a fifty day moving average of $0.50 and a two-hundred day moving average of $0.62.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter. Evoke Pharma had a negative net margin of 116.75% and a negative return on equity of 4,908.09%. The company had revenue of $1.74 million during the quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Articles
- Five stocks we like better than Evoke Pharma
- 3 Monster Growth Stocks to Buy Now
- This Stock’s Price Shifts Into High Gear With Analyst Upgrades
- Using the MarketBeat Dividend Tax Calculator
- AI Boosts Glass Tech Leader Stock: Shares Up 75% and More to Come
- Investing in Construction Stocks
- AI Partnership Boosts This Top Tech Stock: Ready for More Gains?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
